{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:13:20Z","timestamp":1794950000487,"version":"4.9.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CANbridge Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Physiological regulation of transgene expression is a major challenge in gene therapy. Onasemnogene abeparvovec (Zolgensma\n                    <jats:sup>\u00ae<\/jats:sup>\n                    ) is an approved adeno-associated virus (AAV) vector gene therapy for infants with spinal muscular atrophy (SMA), however, adverse events have been observed in both animals and patients following treatment. The construct contains a native human survival motor neuron 1 (\n                    <jats:italic>hSMN1<\/jats:italic>\n                    ) transgene driven by a strong, cytomegalovirus enhancer\/chicken \u03b2-actin (\n                    <jats:italic>CMVen\/CB<\/jats:italic>\n                    ) promoter providing high, ubiquitous tissue expression of SMN. We developed a second-generation AAV9 gene therapy expressing a codon-optimized\n                    <jats:italic>hSMN1<\/jats:italic>\n                    transgene driven by a promoter derived from the native\n                    <jats:italic>hSMN1<\/jats:italic>\n                    gene. This vector restored SMN expression close to physiological levels in the central nervous system and major systemic organs of a severe SMA mouse model. In a head-to-head comparison between the second-generation vector and a benchmark vector, identical in design to onasemnogene abeparvovec, the 2nd-generation vector showed better safety and improved efficacy in SMA mouse model.\n                  <\/jats:p>","DOI":"10.1038\/s44321-024-00037-x","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T06:02:06Z","timestamp":1709013726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-1243","authenticated-orcid":false,"given":"Qing","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5916-3953","authenticated-orcid":false,"given":"Xiupeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8750-8354","authenticated-orcid":false,"given":"Yijie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Jalinous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-1624","authenticated-orcid":false,"given":"Zachary","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Gruntman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-8344","authenticated-orcid":false,"given":"Phillip WL","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-9012","authenticated-orcid":false,"given":"Guangping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9565-1567","authenticated-orcid":false,"given":"Jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"37_CR4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, Mercuri E, Rose K, El-Khairi M, Gerber M et al (2021) Risdiplam in type 1 spinal muscular atrophy. N Engl J Med 384:915\u2013923","journal-title":"N Engl J Med"},{"key":"37_CR5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.celrep.2017.10.010","volume":"21","author":"P Bernabo","year":"2017","unstructured":"Bernabo P, Tebaldi T, Groen EJN, Lane FM, Perenthaler E, Mattedi F, Newbery HJ, Zhou H, Zuccotti P, Potrich V et al (2017) In vivo translatome profiling in spinal muscular atrophy reveals a role for SMN protein in ribosome biology. Cell Rep 21:953\u2013965","journal-title":"Cell Rep"},{"key":"37_CR6","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.ymthe.2020.05.011","volume":"28","author":"A Besse","year":"2020","unstructured":"Besse A, Astord S, Marais T, Roda M, Giroux B, Lejeune FX, Relaix F, Smeriglio P, Barkats M, Biferi MG (2020) AAV9-mediated expression of SMN restricted to neurons does not rescue the spinal muscular atrophy phenotype in mice. Mol Ther 28:1887\u20131901","journal-title":"Mol Ther"},{"key":"37_CR7","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1080\/03007995.2021.1947216","volume":"37","author":"M Bischof","year":"2021","unstructured":"Bischof M, Lorenzi M, Lee J, Druyts E, Balijepalli C, Dabbous O (2021) Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Curr Med Res Opin 37:1719\u20131730","journal-title":"Curr Med Res Opin"},{"key":"37_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.omtm.2022.01.013","volume":"24","author":"N Buss","year":"2022","unstructured":"Buss N, Lanigan L, Zeller J, Cissell D, Metea M, Adams E, Higgins M, Kim KH, Budzynski E, Yang L et al (2022) Characterization of AAV-mediated dorsal root ganglionopathy. Mol Ther Methods Clin Dev 24:342\u2013354","journal-title":"Mol Ther Methods Clin Dev"},{"key":"37_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand D, Mohr F, McMillan H, Tukov FF, Montgomery K, Kleyn A, Sun R, Tauscher-Wisniewski S, Kaufmann P, Kullak-Ublick G (2021) Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol 74:560\u2013566","journal-title":"J Hepatol"},{"key":"37_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","volume":"3","author":"TO Crawford","year":"1996","unstructured":"Crawford TO, Pardo CA (1996) The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 3:97\u2013110","journal-title":"Neurobiol Dis"},{"key":"37_CR11","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","volume":"36","author":"O Dabbous","year":"2019","unstructured":"Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guerin A, Pivneva I, Wu EQ, Arjunji R, Feltner D et al (2019) Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv Ther 36:1164\u20131176","journal-title":"Adv Ther"},{"key":"37_CR12","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, Xia S, Bennett CF, Bishop KM, Shefner JM et al (2019) Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology 92:e2492\u2013e2506","journal-title":"Neurology"},{"key":"37_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Beldzinska M, Rose K, Xiong H, Zanoteli E, Baranello G, Bruno C, Vlodavets D, Wang Y et al (2021) Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med 385:427\u2013435","journal-title":"N Engl J Med"},{"key":"37_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.31128\/AJGP-03-21-5924","volume":"51","author":"JE Davidson","year":"2022","unstructured":"Davidson JE, Farrar MA (2022) The changing therapeutic landscape of spinal muscular atrophy. Aust J Gen Pract 51:38\u201342","journal-title":"Aust J Gen Pract"},{"key":"37_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/hmg\/ddq514","volume":"20","author":"E Dominguez","year":"2011","unstructured":"Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P, Carcenac R, Astord S, Pereira de Moura A, Voit T et al (2011) Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 20:681\u2013693","journal-title":"Hum Mol Genet"},{"key":"37_CR16","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1086\/302372","volume":"64","author":"A Echaniz-Laguna","year":"1999","unstructured":"Echaniz-Laguna A, Miniou P, Bartholdi D, Melki J (1999) The promoters of the survival motor neuron gene (SMN) and its copy (SMNc) share common regulatory elements. Am J Hum Genet 64:1365\u20131370","journal-title":"Am J Hum Genet"},{"key":"37_CR17","unstructured":"EVRYSDI [package insert] (2021) Genentech Inc., South San Francisco"},{"key":"37_CR18","first-page":"53569","volume":"3","author":"DN Feather-Schussler","year":"2016","unstructured":"Feather-Schussler DN, Ferguson TS (2016) A battery of motor tests in a neonatal mouse model of cerebral palsy. J Vis Exp 3:53569","journal-title":"J Vis Exp"},{"key":"37_CR19","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E et al (2017) Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732","journal-title":"N Engl J Med"},{"key":"37_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:59\u201365","journal-title":"Nat Biotechnol"},{"key":"37_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","volume":"28","author":"KD Foust","year":"2010","unstructured":"Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Le TT, Morales PR, Rich MM, Burghes AH et al (2010) Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28:271\u2013274","journal-title":"Nat Biotechnol"},{"key":"37_CR22","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/jcpt.13733","volume":"47","author":"F Galletta","year":"2022","unstructured":"Galletta F, Cucinotta U, Marseglia L, Cacciola A, Gallizzi R, Cuzzocrea S, Messina S, Toscano A, Gitto E (2022) Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy. J Clin Pharm Ther 47:1478\u20131481","journal-title":"J Clin Pharm Ther"},{"key":"37_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-9139-6_8","volume":"1950","author":"DJ Gessler","year":"2019","unstructured":"Gessler DJ, Tai PWL, Li J, Gao G (2019) Intravenous infusion of AAV for widespread gene delivery to the nervous system. Methods Mol Biol 1950:143\u2013163","journal-title":"Methods Mol Biol"},{"key":"37_CR24","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.1093\/hmg\/ddv292","volume":"24","author":"SE Gombash","year":"2015","unstructured":"Gombash SE, Cowley CJ, Fitzgerald JA, Iyer CC, Fried D, McGovern VL, Williams KC, Burghes AH, Christofi FL, Gulbransen BD et al (2015) SMN deficiency disrupts gastrointestinal and enteric nervous system function in mice. Hum Mol Genet 24:5665","journal-title":"Hum Mol Genet"},{"issue":"7","key":"37_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/archdischild-2021-323605","volume":"108","author":"VL Gowda","year":"2022","unstructured":"Gowda VL, Fernandez-Garcia MA, Jungbluth H, Wraige E (2022) New treatments in spinal muscular atrophy. Arch Dis Child 108(7):511\u2013517","journal-title":"Arch Dis Child"},{"key":"37_CR26","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","volume":"6","author":"J Guillou","year":"2022","unstructured":"Guillou J, de Pellegars A, Porcheret F, Fremeaux-Bacchi V, Allain-Launay E, Debord C, Denis M, Pereon Y, Barnerias C, Desguerre I et al (2022) Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv 6:4266\u20134270","journal-title":"Blood Adv"},{"key":"37_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","volume":"19","author":"G Hamilton","year":"2013","unstructured":"Hamilton G, Gillingwater TH (2013) Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 19:40\u201350","journal-title":"Trends Mol Med"},{"key":"37_CR28","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1093\/hmg\/ddq330","volume":"19","author":"CR Heier","year":"2010","unstructured":"Heier CR, Satta R, Lutz C, DiDonato CJ (2010) Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet 19:3906\u20133918","journal-title":"Hum Mol Genet"},{"key":"37_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer C, Katz N, Buza EL, Dyer C, Goode T, Bell P, Richman LK, Wilson JM (2018) Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther 29:285\u2013298","journal-title":"Hum Gene Ther"},{"key":"37_CR30","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1089\/hum.2020.167","volume":"31","author":"J Hordeaux","year":"2020","unstructured":"Hordeaux J, Buza EL, Dyer C, Goode T, Mitchell TW, Richman L, Denton N, Hinderer C, Katz N, Schmid R et al (2020a) Adeno-associated virus-induced dorsal root ganglion pathology. Hum Gene Ther 31:808\u2013818","journal-title":"Hum Gene Ther"},{"key":"37_CR31","doi-asserted-by":"publisher","first-page":"eaba9188","DOI":"10.1126\/scitranslmed.aba9188","volume":"12","author":"J Hordeaux","year":"2020","unstructured":"Hordeaux J, Buza EL, Jeffrey B, Song C, Jahan T, Yuan Y, Zhu Y, Bell P, Li M, Chichester JA et al (2020b) MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Sci Transl Med 12:eaba9188","journal-title":"Sci Transl Med"},{"key":"37_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR (2011) Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478:123\u2013126","journal-title":"Nature"},{"key":"37_CR33","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pbio.0050073","volume":"5","author":"Y Hua","year":"2007","unstructured":"Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR (2007) Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 5:e73","journal-title":"PLoS Biol"},{"key":"37_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","volume":"82","author":"Y Hua","year":"2008","unstructured":"Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR (2008) Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82:834\u2013848","journal-title":"Am J Hum Genet"},{"key":"37_CR35","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1016\/j.ymthe.2023.07.020","volume":"31","author":"E Hudry","year":"2023","unstructured":"Hudry E, Aihara F, Meseck E, Mansfield K, McElroy C, Chand D, Tukov FF, Penraat K (2023) Liver injury in cynomolgus monkeys following intravenous and intrathecal scAAV9 gene therapy delivery. Mol Ther 31:2999\u20133014","journal-title":"Mol Ther"},{"key":"37_CR36","doi-asserted-by":"publisher","first-page":"04","DOI":"10.12703\/P7-04","volume":"7","author":"DM Iascone","year":"2015","unstructured":"Iascone DM, Henderson CE, Lee JC (2015) Spinal muscular atrophy: from tissue specificity to therapeutic strategies. F1000Prime Rep 7:04","journal-title":"F1000Prime Rep"},{"key":"37_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42466-021-00162-9","volume":"4","author":"S Jablonka","year":"2022","unstructured":"Jablonka S, Hennlein L, Sendtner M (2022) Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurol Res Pract 4:2","journal-title":"Neurol Res Pract"},{"key":"37_CR38","unstructured":"Kaspar BK, Foust K (2009) Delivery of polynucleotides using recombinant aav9.US20180036431A1. https:\/\/patentimages.storage.googleapis.com\/7d\/03\/75\/ed38bf29b95603\/WO2019094253A1.pdf"},{"key":"37_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155\u2013165","journal-title":"Cell"},{"key":"37_CR40","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96:6307\u20136311","journal-title":"Proc Natl Acad Sci USA"},{"key":"37_CR41","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH (2008) Spinal muscular atrophy. Lancet 371:2120\u20132133","journal-title":"Lancet"},{"key":"37_CR42","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713\u20131722","journal-title":"N Engl J Med"},{"key":"37_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S et al (2021) Current clinical applications of in vivo gene therapy with AAVs. Mol Ther 29:464\u2013488","journal-title":"Mol Ther"},{"key":"37_CR44","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K et al (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625\u2013635","journal-title":"N Engl J Med"},{"key":"37_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS (2022) Spinal muscular atrophy. Nat Rev Dis Primers 8:52","journal-title":"Nat Rev Dis Primers"},{"key":"37_CR46","first-page":"e51162","volume":"11","author":"L Murray","year":"2014","unstructured":"Murray L, Gillingwater TH, Kothary R (2014) Dissection of the transversus abdominis muscle for whole-mount neuromuscular junction analysis. J Vis Exp 11:e51162","journal-title":"J Vis Exp"},{"key":"37_CR47","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/hmg\/ddm367","volume":"17","author":"LM Murray","year":"2008","unstructured":"Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K, Gillingwater TH (2008) Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet 17:949\u2013962","journal-title":"Hum Mol Genet"},{"key":"37_CR48","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2174\/1566524016666161128113338","volume":"16","author":"LA Nash","year":"2016","unstructured":"Nash LA, Burns JK, Chardon JW, Kothary R, Parks RJ (2016) Spinal muscular atrophy: more than a disease of motor neurons? Curr Mol Med 16:779\u2013792","journal-title":"Curr Mol Med"},{"key":"37_CR1","unstructured":"NOVARTIS (2022a) Novartis announces Nature Medicine publication of Zolgensma data demonstrating ageappropriate milestones when treating children with SMA presymptomaticallyhildren-smapresymptomatically. https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-nature-medicine-publication-zolgensma-data-demonstrating-age-appropriate-milestones-when-treating-children-sma-presymptomatically"},{"key":"37_CR2","unstructured":"NOVARTIS (2022b) Zolgensma acute liver failure. https:\/\/www.novartis.com\/news\/zolgensma-acute-liver-failure-update"},{"key":"37_CR49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1089\/hum.2021.116","volume":"33","author":"X Palazzi","year":"2022","unstructured":"Palazzi X, Pardo ID, Sirivelu MP, Newman L, Kumpf SW, Qian J, Franks T, Lopes S, Liu J, Monarski L et al (2022) Biodistribution and tolerability of AAV-PHP.B-CBh-SMN1 in Wistar Han rats and cynomolgus macaques reveal different toxicologic profiles. Hum Gene Ther 33:175\u2013187","journal-title":"Hum Gene Ther"},{"key":"37_CR50","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41434-019-0085-4","volume":"26","author":"R Pattali","year":"2019","unstructured":"Pattali R, Mou Y, Li XJ (2019) AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy. Gene Ther 26:287\u2013295","journal-title":"Gene Ther"},{"key":"37_CR51","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1172\/JCI124120","volume":"129","author":"DM Ramos","year":"2019","unstructured":"Ramos DM, d\u2019Ydewalle C, Gabbeta V, Dakka A, Klein SK, Norris DA, Matson J, Taylor SJ, Zaworski PG, Prior TW et al (2019) Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. J Clin Invest 129:4817\u20134831","journal-title":"J Clin Invest"},{"key":"37_CR52","doi-asserted-by":"crossref","unstructured":"Respress JL, Wehrens XH (2010) Transthoracic echocardiography in mice. J Vis Exp 39:1738","DOI":"10.3791\/1738-v"},{"key":"37_CR53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/jmg.2008.057950","volume":"45","author":"S Rudnik-Schoneborn","year":"2008","unstructured":"Rudnik-Schoneborn S, Heller R, Berg C, Betzler C, Grimm T, Eggermann T, Eggermann K, Wirth R, Wirth B, Zerres K (2008) Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet 45:635\u2013638","journal-title":"J Med Genet"},{"key":"37_CR54","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.echo.2008.07.001","volume":"21","author":"M Scherrer-Crosbie","year":"2008","unstructured":"Scherrer-Crosbie M, Thibault HB (2008) Echocardiography in translational research: of mice and men. J Am Soc Echocardiogr 21:1083\u20131092","journal-title":"J Am Soc Echocardiogr"},{"key":"37_CR55","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/ejhg.2012.222","volume":"21","author":"J Schreml","year":"2013","unstructured":"Schreml J, Riessland M, Paterno M, Garbes L, Rossbach K, Ackermann B, Kramer J, Somers E, Parson SH, Heller R et al (2013) Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585. Eur J Hum Genet 21:643\u2013652","journal-title":"Eur J Hum Genet"},{"key":"37_CR56","doi-asserted-by":"publisher","first-page":"095513","DOI":"10.1101\/pdb.top095513","volume":"2020","author":"M Sena-Esteves","year":"2020","unstructured":"Sena-Esteves M, Gao G (2020) Introducing genes into mammalian cells: viral vectors. Cold Spring Harb Protoc 2020:095513","journal-title":"Cold Spring Harb Protoc"},{"key":"37_CR57","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1093\/hmg\/ddq329","volume":"19","author":"M Shababi","year":"2010","unstructured":"Shababi M, Habibi J, Yang HT, Vale SM, Sewell WA, Lorson CL (2010) Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet 19:4059\u20134071","journal-title":"Hum Mol Genet"},{"key":"37_CR58","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4161\/rna.6.3.8723","volume":"6","author":"NN Singh","year":"2009","unstructured":"Singh NN, Shishimorova M, Cao LC, Gangwani L, Singh RN (2009) A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol 6:341\u2013350","journal-title":"RNA Biol"},{"key":"37_CR59","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","volume":"1860","author":"RN Singh","year":"2017","unstructured":"Singh RN, Howell MD, Ottesen EW, Singh NN (2017) Diverse role of survival motor neuron protein. Biochim Biophys Acta Gene Regul Mech 1860:299\u2013315","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"37_CR60","doi-asserted-by":"publisher","first-page":"263310552097398","DOI":"10.1177\/2633105520973985","volume":"15","author":"RN Singh","year":"2020","unstructured":"Singh RN, Ottesen EW, Singh NN (2020) The first orally deliverable small molecule for the treatment of spinal muscular atrophy. Neurosci Insights 15:2633105520973985","journal-title":"Neurosci Insights"},{"key":"37_CR61","unstructured":"Spinraza [package insert] (2016) Biogen, Inc., Cambridge. Updated 2023"},{"key":"37_CR62","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM et al (2022) Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med 28:1390\u20131397","journal-title":"Nat Med"},{"key":"37_CR63","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1172\/JCI121658","volume":"128","author":"CJ Sumner","year":"2018","unstructured":"Sumner CJ, Crawford TO (2018) Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. J Clin Invest 128:3219\u20133227","journal-title":"J Clin Invest"},{"key":"37_CR64","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41591-022-01889-x","volume":"28","author":"CJ Sumner","year":"2022","unstructured":"Sumner CJ, Crawford TO (2022) Early treatment is a lifeline for infants with SMA. Nat Med 28:1348\u20131349","journal-title":"Nat Med"},{"key":"37_CR65","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/cne.1100","volume":"432","author":"MD Taylor","year":"2001","unstructured":"Taylor MD, Vancura R, Patterson CL, Williams JM, Riekhof JT, Wright DE (2001) Postnatal regulation of limb proprioception by muscle-derived neurotrophin-3. J Comp Neurol 432:244\u2013258","journal-title":"J Comp Neurol"},{"key":"37_CR66","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0165-0270(02)00360-6","volume":"123","author":"JL Tillerson","year":"2003","unstructured":"Tillerson JL, Miller GW (2003) Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. J Neurosci Methods 123:189\u2013200","journal-title":"J Neurosci Methods"},{"key":"37_CR67","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1089\/hum.2021.255","volume":"33","author":"FF Tukov","year":"2022","unstructured":"Tukov FF, Mansfield K, Milton M, Meseck E, Penraat K, Chand D, Hartmann A (2022) Single-dose intrathecal dorsal root ganglia toxicity of onasemnogene abeparvovec in cynomolgus monkeys. Hum Gene Ther 33:740\u2013756","journal-title":"Hum Gene Ther"},{"key":"37_CR68","doi-asserted-by":"publisher","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","volume":"2","author":"CF Valori","year":"2010","unstructured":"Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ, Azzouz M (2010) Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2:35ra42","journal-title":"Sci Transl Med"},{"key":"37_CR3","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","volume":"24","author":"M Van Alstyne","year":"2021","unstructured":"Van Alstyne M, Tattoli I, Delestree N, Recinos Y, Workman E, Shihabuddin LS, Zhang C, Mentis GZ, Pellizzoni L (2021) Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci 24:930\u2013940","journal-title":"Nat Neurosci"},{"key":"37_CR69","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","volume":"44","author":"B Wirth","year":"2021","unstructured":"Wirth B (2021) Spinal muscular atrophy: in the challenge lies a solution. Trends Neurosci 44:306\u2013322","journal-title":"Trends Neurosci"},{"key":"37_CR70","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N (2020) Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet 21:231\u2013261","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"37_CR71","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/mt.2010.279","volume":"19","author":"J Xie","year":"2011","unstructured":"Xie J, Xie Q, Zhang H, Ameres SL, Hung JH, Su Q, He R, Mu X, Seher Ahmed S, Park S et al (2011) MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mole Ther 19:526\u2013535","journal-title":"Mole Ther"},{"key":"37_CR72","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/mt.2011.98","volume":"19","author":"H Zhang","year":"2011","unstructured":"Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, Wang H, Mueller C, Sena-Esteves M, Brown R et al (2011) Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 19:1440\u20131448","journal-title":"Mol Ther"},{"key":"37_CR73","unstructured":"Zolgensma [package insert] (2019) Novartis Gene Therapies, Inc., Bannockburn. Updated 2\/2023."}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00037-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-024-00037-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00037-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:02:46Z","timestamp":1785751366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-024-00037-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,15]]}},"alternative-id":["37"],"URL":"https:\/\/doi.org\/10.1038\/s44321-024-00037-x","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"QX, HM, GG, and JX are inventors of a patent application filed by the University of Massachusetts Chan Medical School on SMA gene therapy. GG is a scientific co-founder of Voyager Therapeutics, Adrenas Therapeutics, AAVAA Therapeutics, and Aspa Therapeutics and holds equity in these companies. PT, GG, and JX are inventors of patents related to AAV-based gene therapy, some of which were licensed to commercial entities. YM, LJ, FW, JY, and ZK are employees of CANbridge Pharmaceuticals. YM, LJ, GC, JY, and ZK hold equity and\/or stock options in CANbridge Pharmaceuticals. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"20"}}